Expectations should adjust accordingly
Wegovy is prescribed for adults with: A BMI of 30 or higher (obesity classification) A BMI of 27 or higher with weight-related health conditions (hypertension, type 2 diabetes, heart disease) A history of weight regain after previous weight loss attempts Clinical Effectiveness Studies show Wegovy users lose an average of 15-22% of their body weight over 68 weeks
Commonly reported effects may include nausea, vomiting, diarrhea, constipation, or decreased appetite, particularly during dose adjustments
Therefore, this study evaluated the association between semaglutide pretreatment and reproductive outcomes in women with overweight and obesity with infertility who had achieved weight reduction prior to conception attempts
These conditions not only present significant health burdens individually, but they also often coexist, amplifying risks and complications